^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    1d
    How to Define the Gastroesophageal Junction. (PubMed, Dig Endosc)
    Furthermore, we will briefly discuss endoscopic treatment, chemotherapy, and surgical treatment for GEJ cancer. Looking ahead, the reclassification of GEJ cancers using the Kyoto international consensus, coupled with comprehensive molecular analyses of tumors, promises to yield valuable insights.
    Review • Journal
    |
    CDX2 (Caudal Type Homeobox 2)
    4d
    PET Imaging Characterization of Sphingosine-1-Phosphate Receptor 2 in a Mouse Model of Esophageal Adenocarcinoma and Metastatic Lymph Node. (PubMed, Mol Pharm)
    Treatment with JTE013 decreased tumor cell proliferation and reduced S1PR2 and α-SMA expression in OE33 cells. Together, our study suggested that [18F]TZ9555 has a substantial preclinical and clinical potential for assessing S1PR2 expression in predicting EAC progression.
    Preclinical • Journal
    |
    S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    5d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    6d
    Gastroesophageal Junction Adenocarcinoma Presenting With De Novo Metastatic Disease and Ovarian Metastasis in a Young Woman With Atypical Chest Pain. (PubMed, Cureus)
    The patient was treated with combination chemotherapy and immune checkpoint inhibition. This case highlights an atypical presentation of advanced gastroesophageal junction adenocarcinoma in a young adult and underscores the importance of early endoscopic evaluation in patients with persistent dysphagia, as well as recognition of uncommon metastatic patterns and the therapeutic implications of biomarker profiling.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Keytruda (pembrolizumab)
    6d
    RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial (clinicaltrials.gov)
    P2, N=184, Not yet recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre
    New P2 trial
    |
    simvastatin
    7d
    Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 amplification • CLDN18.2 positive
    |
    cyclophosphamide • fludarabine IV
    7d
    BGB-53038-101: A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (clinicaltrials.gov)
    P1, N=47, Terminated, BeOne Medicines | N=514 --> 47 | Trial completion date: Dec 2026 --> Apr 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Apr 2026; The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS wild-type
    |
    Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr)
    7d
    A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Huahui Health
    New P1 trial • First-in-human
    8d
    SOS4C: Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples (clinicaltrials.gov)
    P=N/A, N=450, Recruiting, Mayo Clinic | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    9d
    Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett's esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study. (PubMed, Endoscopy)
    Aberrant p53 expression is strongly associated with an increased neoplastic progression risk in BE patients, regardless of the histopathological findings. It may therefore be a better parameter than confirmed LGD on multiple occasions to identify patients who might benefit from ablation therapy.
    Journal
    |
    TP53 (Tumor protein P53)
    9d
    BG-68501-101: A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (clinicaltrials.gov)
    P1, N=103, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=258 --> 103 | Trial completion date: Jul 2028 --> Aug 2026 | Trial primary completion date: Apr 2028 --> Aug 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK2 (Cyclin-dependent kinase 2)
    |
    HER-2 negative
    |
    fulvestrant
    13d
    ERD2021: 68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date